CRISPR NEWS

U.S. patent office issued third CRISPR patent to CVC; indicates it will issue a fourth

On March 12, 2019 the U.S. Patent and Trademark Office issued U.S. Patent No. 10,227,611 (‘the ‘611 patent), to The Regents of the University of California, the University of Vienna, and Dr. Emmanuelle Charpentier (collectively, “CVC”). The patent covers the use of single guide RNA formats in any setting. The ‘611 patent claim priority to a U.S. provisional application, filed by CVC on May 25, 2012. In addition, the U.S. Patent and Trademark Office has issued a notice of allowance in U.S. patent application numbers 13/842,859 (the “‘859 application”), which focuses on compositions and methods for modifying a target DNA molecule in any setting, including animal and human cells, as well as in vitro settings, that are widely used throughout the industry. Of note, the ‘859 application had been examined previously and found allowable in advance of a prior interference proceeding involving the Broad Institute. The associated patent is expected to issue in the next 3-4 months.

View Press Release

LATEST

Sign up to receive updates from the CRISPR Collective

Related News

U.S. Patent and Trademark Office issued U.S. Patent No. 10,266,850 (‘the ‘850 patent), to The Regents of the University of California, the University of Vienna, and Dr. Emmanuelle Charpentier
European Patent Office (EPO) awarded the Doudna-Charpentier team a broad CRISPR-Cas9 patent (EP Patent No. 3 401 400)
U.S. patent office issued third CRISPR patent to CVC; indicates it will issue a fourth
Read moreArrow-down